iBio, Inc. IBIO
0.78 USD -0.02 (-1.89%)
At closeNov 10, 2026, 6:15 PM EST
0.78 -0.01 -0.64%
After hours · Nov 10, 6:15 PM ET
0.77 Day range 0.8003
0.71 52-week range 3.07
- YTD
- -59.59%
- 1 year
- -39.53%
News
benzinga.com iBio Q1 EPS $(0.05) Beats $(0.08) Estimate, Sales $1.075M Beat $20.000K Estimate iBio (AMEX:IBIO) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 54.55 percent increase over losses of $(0.11) per share…
globenewswire.com iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update Presented additional preclinical data supporting IBIO-610's potential to drive fat selective weight loss in combination with GLP-1 therapy
globenewswire.com iBio to Participate in Upcoming Investor Conferences SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and…
benzinga.com Alpha Buying: 3 Beaten-Down Biotech Stocks Backed by a Specialist Investor There are parts of the stock market where I am comfortable doing the research myself.Give me a community bank’s balance sheet, loan portfolio, and deposit information, and I can usually figure out…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap…
benzinga.com iBio Highlights Preclinical Body-Composition Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate, Alone And In Combination With Semaglutide, GLP-1 Receptor Agonist Used To Treat Obesity In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide aloneiBio expects to start first-in-human…
globenewswire.com iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610's Potential to Preserve Muscle in Combination with GLP-1 Therapy In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone iBio expects to start first-in-human…
defenseworld.net Squarepoint Ops LLC Makes New Investment in iBio, Inc. $IBIO Squarepoint Ops LLC acquired a new stake in iBio, Inc. (NASDAQ: IBIO) during the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 498,872 shares of the…
benzinga.com This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.
benzinga.com HC Wainwright & Co. Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7 HC Wainwright & Co. analyst Ananda Ghosh initiates coverage on iBio (NASDAQ:IBIO) with a Buy rating and announces Price Target of $7.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose…
globenewswire.com iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and…
globenewswire.com iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and…
globenewswire.com iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million. ProMIS Neurosciences (NASDAQ:PMN) shares…
benzinga.com iBio Announces New Preclinical Data From Obese Non-Human Primate Study Evaluating IBIO-610, Activin E Antibody Candidate Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approachWhen combined with semaglutide, IBIO-610 drove…
globenewswire.com iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach- benzinga.com Raymond James Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $5 Raymond James analyst Martin Auster initiates coverage on iBio (NASDAQ:IBIO) with a Outperform rating and announces Price Target of $5.
globenewswire.com iBio to Participate in Upcoming Healthcare Investor Conferences SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary…
benzinga.com iBio Begins Human Testing of Obesity Drug Candidate, First Patient Dosed in Company's Initial Clinical Trial iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), a clinical-stage AI-driven innovator developing therapies for cardiometabolic and cardiopulmonary diseases and obesity, today announced the dosing…
globenewswire.com iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition
benzinga.com iBio Q3 EPS $(0.07) Misses $(0.06) Estimate iBio (AMEX:IBIO) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 85.71 percent increase over losses of $(0.49) per…
globenewswire.com iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with…
globenewswire.com iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First participants expected to be dosed in 2Q 2026 SAN…
seekingalpha.com iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript- benzinga.com iBio, Inc. To Host Call On PH-HFpEF Pipeline Expansion, Targets Bispecific Antibody Candidate Selection In Q3 2026 iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a conference call on Tuesday,…
globenewswire.com iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET- benzinga.com iBio Reports Early Study Results Showing Experimental Obesity Drug Reduced Fat in Animals iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced new preclinical data from its obese non-human primate…
globenewswire.com iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie diet Study demonstrated reduction of 6.7% visceral fat and 5.2% total…- benzinga.com Jones Trading Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7 Jones Trading analyst Catherine Novack initiates coverage on iBio (NASDAQ:IBIO) with a Buy rating and announces Price Target of $7.
defenseworld.net iBio (NASDAQ:IBIO) versus Gemini Therapeutics (NASDAQ:GMTX) Critical Review iBio (NASDAQ: IBIO - Get Free Report) and Gemini Therapeutics (NASDAQ: GMTX - Get Free Report) are both manufacturing companies, but which is the superior stock? We will contrast the two companies…- benzinga.com iBio Enters $100M At-The-Market Offering Agreement With Jefferies LLC; Terminates Prior $7.35M ATM Program On February 27, 2026, iBio, Inc., a Delaware corporation (the "Company"), entered into an Open Market Sale AgreementSM (the "ATM Agreement") with Jefferies LLC ("Jefferies") providing for the sale by…
- benzinga.com iBio Files Preliminary Prospectus To Issue Up To $200M In Securities The information contained in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is…
globenewswire.com iBio to Participate in Upcoming Investor Conferences SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive…
defenseworld.net Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX) Vaxxinity (NASDAQ: VAXX - Get Free Report) and iBio (NYSE: IBIO - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on…
benzinga.com iBio Earnings Review: Q2 Summary - benzinga.com iBio Q2 EPS $(0.09) Misses $(0.07) Estimate iBio (AMEX:IBIO) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 81.25 percent increase over losses of $(0.48) per…
globenewswire.com iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway
zacks.com iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com iBio Files Prospectus For Resale Of 11,061,738 Shares Of Common Stock By Selling Stockholders 11,061,738 Shares of Common StockThis prospectus relates to the resale from time to time of up to 11,061,738 shares of common stock, par value $0.001 per share (the "Common Stock") of iBio, Inc. (the…- benzinga.com iBio Announces Private Placement Of Approximately $26M The financing was led by Frazier Life Sciences and included participation from other existing investors.iBio intends to use the net proceeds received from the offering to advance its preclinical…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com iBio Q1 EPS $(0.11) Misses $(0.10) Estimate, Sales $100.000K Beat $25.000K Estimate iBio (AMEX:IBIO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 7.84 percent. This is a 76.09 percent increase over losses of $(0.46) per…
benzinga.com iBio Announces New Preclinical Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate Supported By Preclinical Data Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session